FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Allergy2018; 74(3); 572-582; doi: 10.1111/all.13659

Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses.

Abstract: Insect-bite hypersensitivity (IBH) in horses is a chronic allergic dermatitis caused by insect bites. Horses suffer from pruritic skin lesions, caused by type-I/type-IV allergic reactions accompanied by prominent eosinophil infiltration into the skin. Interleukin-5 (IL-5) is the key cytokine for eosinophils and we have previously shown that targeting IL-5 by vaccination reduces disease symptoms in horses. Here, we analyzed the potential for long-term therapy by assessing a second follow-up year of the previously published study. The vaccine consisted of equine IL-5 (eIL-5) covalently linked to a cucumber mosaic virus-like particle (VLP) containing a universal T cell epitope (CuMVTT ) using a semi-crossover design to follow vaccinated horses during a second treatment season. Thirty Icelandic horses were immunized with 300 μg of eIL-5-CuMVTT without adjuvant. The vaccine was well tolerated and did not reveal any safety concerns throughout the study. Upon vaccination, all horses developed reversible anti-eIL-5 auto-antibody titers. The mean course of eosinophil levels was reduced compared to placebo treatment leading to significant reduction of clinical lesion scores. Horses in their second vaccination year showed a more pronounced improvement of disease symptoms when compared to first treatment year, most likely due to more stable antibody titers induced by a single booster injection. Hence, responses could be maintained over two seasons and the horses remained protected against disease symptoms. Yearly vaccination against IL-5 may be a long-term solution for the treatment of IBH and other eosinophil-mediated diseases in horses and other species including humans.
© 2018 The Authors. Allergy Published by John Wiley & Sons Ltd.
Get Full Text
Publication Date: 2018-11-25 PubMed ID: 30402930PubMed Central: PMC6587569DOI: 10.1111/all.13659Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study examines the use of a vaccine against a type of cytokine known as Interleukin-5 (IL-5) as a long-term therapy for insect-bite hypersensitivity (IBH) in horses. The results indicated that vaccination significantly reduced disease symptoms by lowering eosinophil (types of white blood cells) levels and might be a potential solution to treating eosinophil-mediated diseases in both animals and humans.

Research Context

  • IBH in horses is a chronic allergic condition resulting from insect bites. This results in itchy skin lesions caused by type-I and type-IV allergic reactions and increased infiltration of eosinophils into the skin.
  • IL-5 is a cytokine that plays a key role in the functioning of eosinophils. Previous studies had shown that targeting IL-5 through vaccination can reduce symptoms of the disease.
  • This study extended the previous research by examining the potential for long-term therapy, assessed through a second follow-up year of the prior study.

Research Method

  • The vaccine used in the study was made from equine IL-5 covalently linked to a cucumber mosaic virus-like particle (VLP) with a universal T-cell epitope (CuMV). This combination was tested in a semi-crossover design in a second treatment season.
  • The study involved thirty Icelandic horses who were given the vaccine without an adjuvant. Safety data was collected throughout the study.

Key Findings

  • The vaccine did not raise any safety concerns, and it was well tolerated by all horses.
  • All the horses developed reversible anti-eIL-5 auto-antibody titers after vaccination, with the mean eosinophil level being reduced compared to placebo treatment.
  • This reduction contributed to a significant decrease in clinical lesion scores, signifying a marked improvement in disease symptoms. This improvement was more pronounced in the second year of vaccination compared to the first year, likely due to the more stable antibody titers induced by a single booster injection.
  • These results showed that response to the vaccine could be maintained over two seasons, and the horses remained protected against the disease symptoms.

Conclusion

  • The study concludes that yearly vaccination against IL-5 could potentially serve as a long-term solution for treating IBH and other eosinophil-mediated diseases in horses, as well as other species including humans.

Cite This Article

APA
Fettelschoss-Gabriel A, Fettelschoss V, Olomski F, Birkmann K, Thoms F, Bühler M, Kummer M, Zeltins A, Kündig TM, Bachmann MF. (2018). Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses. Allergy, 74(3), 572-582. https://doi.org/10.1111/all.13659

Publication

Allergy
ISSN: 1398-9995
NlmUniqueID: 7804028
Country: Denmark
Language: English
Volume: 74
Issue: 3
Pages: 572-582

Researcher Affiliations

Fettelschoss-Gabriel, Antonia
  • Department of Dermatology, University Hospital Zurich, Schlieren, Switzerland.
  • Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • Evax AG, Münchwilen, Switzerland.
Fettelschoss, Victoria
  • Department of Dermatology, University Hospital Zurich, Schlieren, Switzerland.
  • Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • Evax AG, Münchwilen, Switzerland.
Olomski, Florian
  • Department of Dermatology, University Hospital Zurich, Schlieren, Switzerland.
  • Faculty of Medicine, University of Zurich, Zurich, Switzerland.
Birkmann, Katharina
  • Evax AG, Münchwilen, Switzerland.
Thoms, Franziska
  • Department of Dermatology, University Hospital Zurich, Schlieren, Switzerland.
  • Faculty of Medicine, University of Zurich, Zurich, Switzerland.
Bühler, Maya
  • Thurlandpraxis, Niederuzwil, Switzerland.
Kummer, Martin
  • Thurlandpraxis, Niederuzwil, Switzerland.
Zeltins, Andris
  • Latvian Biomedical Research & Study Centre, Riga, Latvia.
Kündig, Thomas M
  • Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Bachmann, Martin F
  • RIA Immunology, Inselspital, University of Bern, Bern, Switzerland.
  • The Jenner Institute, Nuffield Department of Medicine, The Henry Wellcome Building for Molecular Physiology, University of Oxford, Oxford, UK.

MeSH Terms

  • Allergens / chemistry
  • Allergens / immunology
  • Animals
  • Eosinophils / immunology
  • Eosinophils / metabolism
  • Epitope Mapping
  • Epitopes / chemistry
  • Epitopes / immunology
  • Horse Diseases / etiology
  • Horse Diseases / therapy
  • Horses
  • Hypersensitivity / veterinary
  • Immunization
  • Immunoglobulin E / immunology
  • Insect Bites and Stings / complications
  • Interleukin-5 / chemistry
  • Interleukin-5 / immunology
  • Leukocyte Count
  • Models, Molecular
  • Protein Conformation
  • Structure-Activity Relationship
  • Vaccines, Virus-Like Particle / administration & dosage
  • Vaccines, Virus-Like Particle / immunology

Grant Funding

  • 25758.1 PFLS-LS / Commission for Technology and Innovation
  • CRSII3_154490 / Swiss National Science Foundation
  • Benchmark Vaccines Limited, UK.

Conflict of Interest Statement

AFG, VF, FT, KB, MB, MK, TMK, and MFB are involved in the development of active immunotherapies. The authors FO and AZ have no conflict of interests to disclose.

References

This article includes 34 references
  1. Baker KP, Quinn PJ. A report on clinical aspects and histopathology of sweet itch.. Equine Vet J 1978;10:243‐248.
    pubmed: 738265
  2. Braverman Y, Ungar‐Waron H, Frith K. Epidemiological and immunological studies of sweet itch in horses in Israel.. Vet Rec 1983;112:521‐524.
    pubmed: 6879963
  3. Anderson GS, Belton P, Jahren E, Lange H, Kleider N. Immunotherapy trial for horses in British Columbia with Culicoides (Diptera: Ceratopogonidae) hypersensitivity.. J Med Entomol 1996;33:458‐466.
    pubmed: 8667395
  4. Kurotaki T, Narayama K, Oyamada T, Yoshikawa H, Yoshikawa T. Immunopathological study on equine insect hypersensitivity (“kasen”) in Japan.. J Comp Pathol 1994;110:145‐152.
    pubmed: 8040382
  5. Anderson GS, Belton P, Kleider N. Culicoides obsoletus (Diptera: Ceratopogonidae) as a causal agent of Culicoides hypersensitivity (sweet itch) in British Columbia.. J Med Entomol 1991;28:685‐693.
    pubmed: 1941937
  6. Quinn PJ, Baker KP, Morrow AN. Sweet itch: responses of clinically normal and affected horses to intradermal challenge with extracts of biting insects.. Equine Vet J 1983;15:266‐272.
    pubmed: 6884318
  7. Fadok VA, Greiner EC. Equine insect hypersensitivity: skin test and biopsy results correlated with clinical data.. Equine Vet J 1990;22:236‐240.
    pubmed: 1976506
  8. Greiner EC, Fadok VA, Rabin EB. Equine Culicoides hypersensitivity in Florida: biting midges aspirated from horses.. Med Vet Entomol 1990;4:375‐381.
    pubmed: 2133005
  9. Fettelschoss‐Gabriel A, Fettelschoss V, Thoms F. Treating insect‐bite hypersensitivity in horses with active vaccination against IL‐5.. J Allergy Clin Immunol 2018;142:1194‐1205.
    pubmed: 29627082
  10. Bachmann MF, Dyer MR. Therapeutic vaccination for chronic diseases: a new class of drugs in sight.. Nat Rev Drug Discov 2004;3:81‐88.
    pubmed: 14666113
  11. Dunshea FR, Colantoni C, Howard K. Vaccination of boars with a GnRH vaccine (Improvac) eliminates boar taint and increases growth performance.. J Anim Sci 2001;79:2524‐2535.
    pubmed: 11721830
  12. Baker DL, Powers JG, Ransom JI. Reimmunization increases contraceptive effectiveness of gonadotropin‐releasing hormone vaccine (GonaCon‐Equine) in free‐ranging horses (Equus caballus): limitations and side effects.. PLoS One 2018;13:e0201570.
    pmc: PMC6067756pubmed: 30063758
  13. Chackerian B, Frietze KM. Moving towards a new class of vaccines for non‐infectious chronic diseases.. Expert Rev Vaccines 2016;15:561‐563.
    pubmed: 26919571
  14. . Noninfectious Disease Vaccines (41).. .
  15. Schaffartzik A, Hamza E, Janda J, Crameri R, Marti E, Rhyner C. Equine insect bite hypersensitivity: what do we know?. Vet Immunol Immunopathol 2012;147:113‐126.
    pubmed: 22575371
  16. Foster AP, McKelvie J, Cunningham FM. Inhibition of antigen‐induced cutaneous responses of ponies with insect hypersensitivity by the histamine‐1 receptor antagonist chlorpheniramine.. Vet Rec 1998;143:189‐193.
    pubmed: 9762759
  17. Benarafa C, Collins ME, Hamblin AS, Cunningham FM. Role of the chemokine eotaxin in the pathogenesis of equine sweet itch.. Vet Rec 2002;151:691‐693.
    pubmed: 12503787
  18. Collins PD, Marleau S, Griffiths‐Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin‐5 and the chemokine eotaxin to induce eosinophil accumulation in vivo.. J Exp Med 1995;182:1169‐1174.
    pmc: PMC2192289pubmed: 7561691
  19. Palframan RT, Collins PD, Williams TJ, Rankin SM. Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow.. Blood 1998;91:2240‐2248.
    pubmed: 9516121
  20. Benarafa C, Collins ME, Hamblin AS, Sabroe I, Cunningham FM. Characterisation of the biological activity of recombinant equine eotaxin in vitro.. Cytokine 2002;19:27‐30.
    pubmed: 12200110
  21. Strath M, Dent L, Sanderson C. Infection of IL5 transgenic mice with Mesocestoides corti induces very high levels of IL5 but depressed production of eosinophils.. Exp Hematol 1992;20:229‐234.
    pubmed: 1544392
  22. Kopf M, Brombacher F, Hodgkin PD. IL‐5‐deficient mice have a developmental defect in CD5 + B‐1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses.. Immunity 1996;4:15‐24.
    pubmed: 8574848
  23. Legrand F, Klion AD. Biologic therapies targeting eosinophils: current status and future prospects.. J Allergy Clin Immunol Pract 2015;3:167‐174.
    pmc: PMC4418449pubmed: 25754717
  24. Roufosse F. Targeting the interleukin‐5 pathway for treatment of eosinophilic conditions other than asthma.. Front Med (Lausanne) 2018;5:49.
    pmc: PMC5897501pubmed: 29682504
  25. Zeltins A, West J, Zabel F. Incorporation of tetanus‐epitope into virus‐like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy.. Vaccines 2017;2:30.
    pmc: PMC5653761pubmed: 29263885
  26. Kallberg M, Wang H, Wang S. Template‐based protein structure modeling using the RaptorX web server.. Nat Protoc 2012;7:1511‐1522.
    pmc: PMC4730388pubmed: 22814390
  27. Kusano S, Kukimoto‐Niino M, Hino N. Structural basis of interleukin‐5 dimer recognition by its alpha receptor.. Protein Sci 2012;21:850‐864.
    pmc: PMC3403420pubmed: 22528658
  28. Zhang J, Kuvelkar R, Murgolo NJ. Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL‐5.. Int Immunol 1999;11:1935‐1944.
    pubmed: 10590259
  29. Khairy WOA, Qian K, Shao H, Ye J, Qin A. Identification of two conserved B‐cell epitopes in the gp90 of reticuloendothelial virus using peptide microarray.. Vet Microbiol 2017;211:107‐111.
    pubmed: 29102104
  30. Jegerlehner A, Storni T, Lipowsky G, Schmid M, Pumpens P, Bachmann MF. Regulation of IgG antibody responses by epitope density and CD21‐mediated costimulation.. Eur J Immunol 2002;32:3305‐3314.
    pubmed: 12555676
  31. Cavelti‐Weder C, Timper K, Seelig E. Development of an interleukin‐1β vaccine in patients with type 2 diabetes.. Mol Ther 2016;24:1003‐1012.
    pmc: PMC4881764pubmed: 26686385
  32. Kita HAC, Gleich GJ. Biology of Eosinophils.. .
  33. Park YM, Bochner BS. Eosinophil survival and apoptosis in health and disease.. Allergy Asthma Immunol Res 2010;2:87‐101.
    pmc: PMC2846745pubmed: 20358022
  34. Mesnil C, Raulier S, Paulissen G. Lung‐resident eosinophils represent a distinct regulatory eosinophil subset.. J Clin Invest 2016;126:3279‐3295.
    pmc: PMC5004964pubmed: 27548519

Citations

This article has been cited 24 times.
Subscribe to our newsletter
Join 100,151 horse owners like you who receive our email updates on horse health and nutrition.